Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Duquesne Family Office LLC

Duquesne Family Office LLC raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 65.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 14,879,750 shares of the company's stock after acquiring an additional 5,882,350 shares during the period. Teva Pharmaceutical Industries makes up 7.5% of Duquesne Family Office LLC's investment portfolio, making the stock its 2nd largest holding. Duquesne Family Office LLC owned 1.31% of Teva Pharmaceutical Industries worth $228,702,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Pinnbrook Capital Management LP purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $4,966,000. Asset Management One Co. Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock valued at $10,414,000 after purchasing an additional 58,413 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Teva Pharmaceutical Industries by 2,018.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after purchasing an additional 1,045,305 shares in the last quarter. Capital Wealth Planning LLC increased its holdings in shares of Teva Pharmaceutical Industries by 8.8% in the 4th quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock valued at $5,435,000 after purchasing an additional 20,016 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $38,914,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $24.44.

Teva Pharmaceutical Industries Trading Down 4.0%

Shares of Teva Pharmaceutical Industries stock traded down $0.71 during mid-day trading on Friday, hitting $17.00. 13,361,575 shares of the stock were exchanged, compared to its average volume of 10,188,168. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The stock has a market capitalization of $19.49 billion, a price-to-earnings ratio of -11.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60. The company has a 50-day simple moving average of $16.04 and a 200 day simple moving average of $17.42. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same period last year, the company earned $0.48 EPS. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. Research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Insider Buying and Selling

In related news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president now owns 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.